Target intelligence / Profile preview

Alcohol dehydrogenase 1 (Equus caballus) (HLADH) (HLADH)

Target
HLADH
Molecular classification
Enzyme, Oxidoreductase, Zinc-binding protein, Medium-chain dehydrogenase/reductase (MDR) family (UniProt P00327)
01

Overview

Horse liver alcohol dehydrogenase (HLADH) is a dimeric, zinc-dependent oxidoreductase that serves as a primary model for the study of alcohol metabolism and enzyme kinetics. It catalyzes the reversible oxidation of a wide range of primary and secondary alcohols to their corresponding aldehydes and ketones, utilizing nicotinamide adenine dinucleotide (NAD+) as a cofactor (UniProt P00327). In clinical toxicology, the human ortholog of this enzyme is a critical therapeutic target; inhibiting its activity prevents the conversion of relatively non-toxic substances like methanol and ethylene glycol into highly toxic metabolites such as formic acid and oxalic acid (StatPearls, 2023). Fomepizole is a potent competitive inhibitor of HLADH and is the standard treatment for such poisonings (PubChem). Beyond its medical relevance, HLADH is extensively used in organic synthesis and industrial biocatalysis due to its broad substrate specificity and high degree of stereoselectivity (Journal of Biological Chemistry). The enzyme consists of two subunits, often designated E (ethanol-active) and S (steroid-active), which form various isoenzymes with distinct substrate preferences.

Other names
Horse liver alcohol dehydrogenaseAlcohol dehydrogenase E chainAlcohol dehydrogenase S chainADH1Alcohol:NAD+ oxidoreductaseLiver alcohol dehydrogenase
02

Mechanism of action

Competitive inhibition of the enzyme active site by binding to the catalytic zinc ion, thereby preventing the oxidation of alcohol substrates into their corresponding toxic aldehydes (StatPearls, 2023).

03

Biological functions

Alcohol metabolismRetinol metabolismOxidation of primary and secondary alcoholsReduction of aldehydes and ketones (UniProt P00327)
04

Disease associations

Methanol poisoningEthylene glycol poisoningAlcohol use disorderFormaldehyde toxicity (StatPearls, 2023)
05

Safety considerations

Metabolic acidosis (StatPearls, 2023)Central nervous system depression (NIH, 2023)Accumulation of parent alcohols (PubChem)Potential for drug-drug interactions with other alcohol-metabolized substrates
06

Interacting drugs

Fomepizole

5 more in the full profile.

07

Biomarkers

Serum ethanol concentrationSerum methanol concentrationSerum ethylene glycol concentrationAnion gapOsmolar gap (StatPearls, 2023)

Beyond the preview

Go deeper on Alcohol dehydrogenase 1 (Equus caballus) (HLADH) (HLADH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alcohol dehydrogenase 1 (Equus caballus) (HLADH) (HLADH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call